Bruker (NASDAQ:BRKR) Price Target Raised to $60.00

Bruker (NASDAQ:BRKR) had its target price upped by Bank of America from $43.00 to $60.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the medical research company’s stock.

Several other equities analysts also recently issued reports on the stock. Cowen reissued a “hold” rating on shares of Bruker in a research note on Tuesday, November 4th. Wells Fargo & Company increased their price target on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday. Redburn Partners set a $60.00 price objective on Bruker in a report on Thursday, November 20th. Weiss Ratings reiterated a “sell (d)” rating on shares of Bruker in a research note on Monday, December 1st. Finally, TD Cowen increased their target price on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus price target of $52.86.

Bruker Stock Performance

NASDAQ BRKR opened at $44.41 on Monday. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $64.64. The business has a fifty day moving average of $42.26 and a 200-day moving average of $38.49. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of -277.56, a price-to-earnings-growth ratio of 6.62 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The business had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. During the same quarter last year, the company earned $0.60 earnings per share. The business’s revenue for the quarter was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, analysts predict that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, December 8th. Bruker’s payout ratio is currently -125.00%.

Insider Activity

In related news, Director John A. Ornell sold 6,233 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 27.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BRKR. Nisa Investment Advisors LLC raised its stake in shares of Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the period. Allworth Financial LP increased its holdings in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Huntington National Bank raised its position in Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the period. Spire Wealth Management acquired a new position in shares of Bruker during the second quarter worth about $32,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after buying an additional 745 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.